Eyebright Medical Morgan Bond
688050 Stock | 90.61 1.90 2.05% |
At present, Eyebright Medical's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt is expected to grow to about 142.4 M, whereas Net Debt is forecasted to decline to (181.5 M). With a high degree of financial leverage come high-interest payments, which usually reduce Eyebright Medical's Earnings Per Share (EPS).
At present, Eyebright Medical's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 2.7 B, whereas Non Current Liabilities Other is forecasted to decline to about 1.1 M. Eyebright |
Given the importance of Eyebright Medical's capital structure, the first step in the capital decision process is for the management of Eyebright Medical to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Eyebright Medical Technology to issue bonds at a reasonable cost.
Popular Name | Eyebright Medical Morgan Stanley 3591 |
Specialization | Health Care Equipment & Services |
Equity ISIN Code | CNE1000041J5 |
Bond Issue ISIN Code | US61744YAK47 |
S&P Rating | Others |
Maturity Date | 22nd of July 2028 |
Issuance Date | 24th of July 2017 |
Coupon | 3.591 % |
Eyebright Medical Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details |
Understaning Eyebright Medical Use of Financial Leverage
Eyebright Medical's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Eyebright Medical's total debt position, including all outstanding debt obligations, and compares it with Eyebright Medical's equity. Financial leverage can amplify the potential profits to Eyebright Medical's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Eyebright Medical is unable to cover its debt costs.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 187.2 M | 196.6 M | |
Net Debt | -172.9 M | -181.5 M | |
Short Term Debt | 805 K | 764.8 K | |
Short and Long Term Debt | 135.6 M | 142.4 M | |
Long Term Debt | 258.5 M | 202.3 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Eyebright Stock
Eyebright Medical financial ratios help investors to determine whether Eyebright Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eyebright with respect to the benefits of owning Eyebright Medical security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.